GSK - GlaxoSmithKline plc

NYSE - NYSE Delayed Price. Currency in USD
39.39
-0.07 (-0.18%)
At close: 4:02PM EDT

39.39
After hours: 4:44PM EDT

Stock chart is not supported by your current browser
Previous Close39.46
Open39.28
Bid39.31 x 1000
Ask39.42 x 1800
Day's Range39.26 - 39.53
52 Week Range36.41 - 42.36
Volume1,705,437
Avg. Volume2,407,004
Market Cap100.157B
Beta (3Y Monthly)0.52
PE Ratio (TTM)39.71
EPS (TTM)0.99
Earnings DateFeb 1, 2017 - Feb 6, 2017
Forward Dividend & Yield2.39 (5.81%)
Ex-Dividend Date2019-05-16
1y Target Est44.33
Trade prices are not sourced from all markets
  • Primary Drivers of the Chinese Economy
    Investopedia6 hours ago

    Primary Drivers of the Chinese Economy

    Learn about the forces driving the Chinese economy and helping the country earn money. China has the first or second largest GDP in the world but is not nearly as developed as others in the top 10.

  • Thermo Fisher Acquires GlaxoSmithKline's Drug Production Site
    Zacks3 days ago

    Thermo Fisher Acquires GlaxoSmithKline's Drug Production Site

    The latest acquisition aligns with Thermo Fisher's (TMO) strategy of enhancing capabilities of its Pharma Services through the right balance of capital investment, and merger and acquisition.

  • Reuters4 days ago

    GSK and Novartis liniment marketing misled Australian consumers - court

    The Australian subsidiaries of British drugmaker GlaxoSmithKline and Swiss drugmaker Novartis misled customers and broke the law by promoting identical liniments as though they could treat specific ills, an Australian court found on Friday. The court said the companies admitted marketing Voltaren Osteo Gel as a treatment for osteoarthritis-related pain when its ingredients were the same as a cheaper Voltaren product, Emulgel. Judge Robert Bromwich said in a written decision that it was part of a "deliberate and considered marketing strategy".

  • GuruFocus.com4 days ago

    How to Invest in Biotech: Known Your Catalysts

    The biotechnology and pharmaceutical industry has something for everyone. Whether you are looking for a mature dividend aristocrat like GlaxoSmithKline (GSK) or a small-cap upstart like Sarepta (SRPT) that can double in value overnight, the sector will provide an option that suits your preferred risk-reward profile. Warning! GuruFocus has detected 5 Warning Sign with GSK.

  • PR Newswire5 days ago

    Thermo Fisher Scientific to Acquire Manufacturing Site in Cork, Ireland, from GSK

    Expands global footprint for complex API manufacturing WALTHAM, Mass. , May 16, 2019 /PRNewswire/ -- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced today that ...

  • GlobeNewswire6 days ago

    Matinas BioPharma Announces a Research Collaboration with ViiV Healthcare to Evaluate Formulation of Antiviral Drug Candidates

    Formulations of select antivirals will be developed using Matinas’ LNC platform delivery technology, which enables the development of a wide range of difficult-to-deliver molecules. Promising formulations will be tested in in vivo preclinical studies to identify a lead LNC-antiviral formulation to take forward in development.

  • Stanford Dad Accused of $6.5 Million Payment in College Scandal Has a New Problem
    Bloomberg7 days ago

    Stanford Dad Accused of $6.5 Million Payment in College Scandal Has a New Problem

    Shandong Buchang Pharmaceuticals Co., whose chairman Zhao Tao has been caught up in the U.S. college admissions scandal, said in a statement Monday that it had received questions from the stock exchange over why its sales expenses amounted to a higher-than-average 59% of the company’s 2018 revenue of 13.7 billion yuan ($1.99 billion). The company, which sells herbal medicines and bio-pharmaceuticals, said that the sales expenses were for general marketing and consulting, but did not explain why it was higher than the industry average.

  • Top vaccine makers Merck and Pfizer target China and older adults next
    CNBC8 days ago

    Top vaccine makers Merck and Pfizer target China and older adults next

    Four giant companies now dominate global vaccine sales. With newer and more expensive vaccines becoming available, the market value of vaccines could rise to $100 billion by 2025.

  • Reuters12 days ago

    GSK-Pfizer deal gets approval from Australia's anti-trust watchdog

    The two pharmaceutical giants in December said they would combine their consumer health businesses in a joint venture that would be 68 percent-owned by GSK. The Australian Competition and Consumer Commission (ACCC) said products produced and sold by GSK and Pfizer in Australia would face strong competition from other players. For example, GSK's well-known pain management product - Panadol - would face strong competition from Reckitt Benckiser's Nurofen.

  • Reuters12 days ago

    Australia's anti-trust watchdog gives go-ahead for GSK-Pfizer consumer healthcare deal

    Australia's competition regulator said on Thursday it will not oppose GlaxoSmithKline's deal to buy Pfizer's consumer healthcare business. The two pharmaceutical giants said in December they would combine ...

  • Theravance (TBPH) Q1 Loss Widens, Revenues Miss Estimates
    Zacks12 days ago

    Theravance (TBPH) Q1 Loss Widens, Revenues Miss Estimates

    Theravance Biopharma (TBPH) retains its earlier issued guidance for 2019 operating loss sans non-cash share-based compensation in the range of $210-$230 million.

  • Clovis (CLVS) Q1 Earnings Top Estimates, Rubraca Sales Strong
    Zacks12 days ago

    Clovis (CLVS) Q1 Earnings Top Estimates, Rubraca Sales Strong

    Clovis (CLVS) reports encouraging first-quarter 2019 results. Rubraca maintains market share during the quarter.

  • Comparing the EPS Growth Trajectories of PFE and GSK
    Market Realist13 days ago

    Comparing the EPS Growth Trajectories of PFE and GSK

    Pfizer or GlaxoSmithKline: Which Is a Better Pick in May?(Continued from Prior Part)EPS performanceOn its first-quarter earnings conference call, Pfizer (PFE) increased its 2019 adjusted diluted EPS guidance by $0.01 at the midpoint to

  • What Are Analysts Recommending for PFE and GSK in May?
    Market Realist13 days ago

    What Are Analysts Recommending for PFE and GSK in May?

    Pfizer or GlaxoSmithKline: Which Is a Better Pick in May?(Continued from Prior Part)Milestones achieved in MayOn May 6, Pfizer (PFE) issued a press release announcing the FDA’s approval of two oral formulations of tafamidis, Vyndaqel and Vyndamax,

  • What's in Store for Axsome (AXSM) This Earnings Season?
    Zacks13 days ago

    What's in Store for Axsome (AXSM) This Earnings Season?

    On Axsome's (AXSM) first-quarter earnings call, investors will look for its progress with the CNS pipeline candidates and the regulatory updates on the same.

  • Comparing the Relative Valuations of PFE and GSK
    Market Realist13 days ago

    Comparing the Relative Valuations of PFE and GSK

    Pfizer or GlaxoSmithKline: Which Is a Better Pick in May?First-quarter performancePfizer (PFE) and GlaxoSmithKline (GSK) reported their first-quarter earnings results on April 30 and May 1, respectively.In the first quarter, Pfizer surpassed

  • The Zacks Analyst Blog Highlights: Merck, Pfizer, AbbVie, Sanofi and Glaxo
    Zacks14 days ago

    The Zacks Analyst Blog Highlights: Merck, Pfizer, AbbVie, Sanofi and Glaxo

    The Zacks Analyst Blog Highlights: Merck, Pfizer, AbbVie, Sanofi and Glaxo

  • UK's Vectura wins patent infringement case against GlaxoSmithKline in U.S
    Reuters16 days ago

    UK's Vectura wins patent infringement case against GlaxoSmithKline in U.S

    A jury trial in a Delaware district court on Friday found that one of Vectura's U.S. patents was infringed by sales of three of GSK's Ellipta products in the United States, Vectura said. The jury found that GSK, which is also a UK-based pharmaceutical company, willfully infringed the patent, which Vectura said gives it the right to seek enhanced damages. Vectura expects to seek application of the 3 percent royalty to sales of the infringing products through the end of the patent term in mid-2021, it said.

  • Reuters16 days ago

    UK's Vectura wins patent infringement case against GlaxoSmithKline in U.S.

    British drugmaker Vectura Group Plc said on Saturday that it won a patent infringement litigation case against GlaxoSmithKline Plc in the United States and has been awarded $89.7 million in damages for the period from August 2016 through December 2018. A jury trial in a Delaware district court on Friday found that one of Vectura's U.S. patents was infringed by sales of three of GSK's Ellipta products in the United States, Vectura said. The jury found that GSK, which is also a UK-based pharmaceutical company, willfully infringed the patent, which Vectura said gives it the right to seek enhanced damages.

  • Emergent (EBS) Earnings & Revenues Miss Estimates in Q1
    Zacks17 days ago

    Emergent (EBS) Earnings & Revenues Miss Estimates in Q1

    Emergent (EBS) incurs loss in the first quarter and misses on revenues as well.

  • Gilead (GILD) Earnings Beat, Revenues Miss Estimates in Q1
    Zacks17 days ago

    Gilead (GILD) Earnings Beat, Revenues Miss Estimates in Q1

    Biotech bigwig Gilead's (GILD) Q1 financial report is mixed with dismal sales and an earnings beat.

  • Pharma Stock Roundup: MRK, LLY, PFE Report Q1 Earnings, SNY, ABBV  Drugs Get EU Nod
    Zacks18 days ago

    Pharma Stock Roundup: MRK, LLY, PFE Report Q1 Earnings, SNY, ABBV Drugs Get EU Nod

    Merck (MRK), Pfizer (PFE), Lilly (LLY) announce Q1 results. European Commission grants approval to AbbVie's (ABBV) Skyrizi and Sanofi's (SNY) Zynquista.

  • Reuters18 days ago

    UK Stocks-Factors to watch on May 3

    (Adds company news items and futures) May 3 (Reuters) - Britain's FTSE 100 index is seen opening 1 point higher at 7,352 on Friday, according to financial bookmakers, while FTSE 100 futures were up 0.13 ...

  • The money behind vaccines
    CNBC Videos8 days ago

    The money behind vaccines

    Vaccines are one of the biggest successes of modern medicine. They save up to 3 million people worldwide every year. From research and discovery to product development, it can cost up to a billion dollars to make one vaccine, and that process — can last up to 15 years. During the past few decades the number of companies producing vaccines has dwindled to just a handful. The four big drug companies that now dominate the market are Merck, Pfizer, Sanofi Pasteur and GlaxoSmithKline.